← Leaderboards
Jonathan Paul Fleegel
Creighton University
$128,617
Attributed
$128,617
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $45.2K · FY2021–23$50K$37.5K$25K$12.5K$0
'21
'22
'23
Funding mix
By agency
NIH$128,617 · 1
By mechanism
F30$128,617 · 1
Top collaborators
No co-investigators on record.
Most similar at Creighton University
Same institution · by research overlap
- Tal Teitz$2,542,267
- Bernd Fritzsch$4,779,338
- Heather Colleen Jensen-Smith$1,123,303
Others in their field
Other Emerging Leaders on “Adult”
- Beth Baseler · Leidos Biomedical Research, Inc.$127,607,354
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$93,592,175
- Susan M Landau · University Of California Berkeley$47,252,026
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$42,295,422
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Evan Z Macosko · Broad Institute, Inc.$32,116,761
Research focus
AdultCostAminoglycoside AntibioticsAminoglycoside-Induced OtotoxicityAminoglycosidesAcvr1 GeneAntibioticsAreaAuditoryAuditory Brainstem ResponsesBackBacterial InfectionsAdverse EffectsCareer ChoiceCell InjuryCellsChildClinicClinically RelevantCochleaCombatCommunicationCommunitiesCytoprotection
Grant awards (3)
Repurposing momelotinib for the prevention of aminoglycoside-induced ototoxicity$38,921
F30 · FY2023 · DC · contact PI
Repurposing momelotinib for the prevention of aminoglycoside-induced ototoxicity$45,206
F30 · FY2022 · DC · contact PI
Repurposing momelotinib for the prevention of aminoglycoside-induced ototoxicity$44,490
F30 · FY2021 · DC · contact PI